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DAPPENDIX 1. INCLUSION AND EXCLUSION
CRITERIA
TRITON trial inclusion criteria were as follows: patient
aged 18 years or more; patient who has aortic stenosis or
stenosis insufficiency of an aortic valve requiring a planned
replacement as indicated in the preoperative evaluation; pa-
tient who is scheduled to undergo planned AVR with or
without concomitant coronary bypass surgery; patient
who has signed and dated the study informed consent
form before study procedures; and patient who is geograph-
ically stable and agrees to attend follow-up assessments at
the hospital of surgical services for a maximum of 5 years.
TRITON trial exclusion criteria were as follows: patient
with pure aortic insufficiency; patient who requires emer-
gency surgery; patient with an aneurysm of the aortic root
or ascending aorta requiring surgical intervention; patient
with a left ventricular ejection fraction less than 25%; pa-
tient with a congenital bicuspid aortic valve; patient who
has had active endocarditis within 3 months before the
scheduled AVR surgery; patient with concomitant valve
(mitral, tricuspid, pulmonic) disease requiring repair with
an annuloplasty ring or replacement with a prosthesis; pa-
tient who has had prior mitral prior mitral, tricuspid, or pul-
monic valve surgery, which included implantation of
a bioprosthetic valve, mechanical valve, or annuloplasty
ring that will remain in situ; patient who has had a myocar-
dial infarction within 1 month before the scheduled AVR
surgery; patient who has a noncardiac disease limiting life
expectancy to less than 12 months; patient who previously
received an EDWARDS INTUITY (Edwards Lifesciences
LLC, Irvine, Calif) valve implant; patient who is an intrave-
nous drug abuser; patient who is female or lactating; patient
who is currently participating in another drug or device clin-
ical investigation; and patient with documented blood
diathesis.APPENDIX 2. END POINT DEFINITIONS
Embolism is defined as a free-flowing blood clot or lesion
material that is located in the systemic or pulmonary
circulation that occurs in the absence of infection afterThe Journal of Thoracic and Caimmediate perioperative period. It may be manifested as
a neurologic event or noncerebral embolic event; a noncere-
bral event is an embolus documented operatively, clinically,
or during autopsy that produces signs and symptoms due
to partial or complete obstruction of a peripheral artery.
The event excludes postoperative myocardial infarction
unless detected by operation, clinical imaging, autopsy, or
emboli due to nonthrombotic material (atherosclerosis,
myxoma).
Valve thrombosis is defined as a blood clot not associated
with infection, causing dysfunction of the heart valve sub-
stitute. Diagnosis is confirmed by echocardiography, angio-
cardiography or magnetic resonance imaging, operation,
explant, or autopsy.
Bleeding event is defined as any episode of major internal
or external bleeding that causes death, hospitalization, or
permanent injury (eg, vision loss) or necessitates transfu-
sion. Major bleeding unexpectedly associated with minor
trauma should be reported as a bleeding event, but bleeding
associated with major trauma or a major operation is con-
sidered secondary to those events and should not be re-
ported. Bleeding events are reported for all patients
regardless of whether they are taking anticoagulants or anti-
platelet drugs. Although total bleeding events must be re-
ported, bleeding events also can be reported separately for
those who are taking anticoagulants or antiplatelet agents
and those who are not.
Paravalvular leak is defined as a clinically or hemody-
namically detectable defect between the heart valve substi-
tute and the patient’s annulus.
Endocarditis is an inflammation or infection of the endo-
cardium, which is the inner lining of the heart muscle and,
most commonly, the heart valves, typically caused by bac-
terial infection but can be caused by fungus. An infection
for which no source is identified and may or may not be
associated with classic signs of endocarditis (eg, red blood
cell casts in urine, splinter hemorrhages in finger nails, roof
of mouth, lesions on retina) and may or may not be associ-
ated with a vegetation inside the atrium or on a valve. Event
must be confirmed by 2 consecutive positive blood cultures
or imaging study, explant, or autopsy.
Technical success was defined as delivery and deploy-
ment of the study valve within 2 attempts.
Procedural success was defined as technical success and
the absence of complications requiring device reoperation,
permanent pacemaker implant (with baseline sinus rhythm
and no conduction issues), or death.Discussion
Dr G. Hossein Almassi (Milwaukee, Wis). You have a high in-
cidence of primary pacemaker implantation. Is it something
related to the design of the valve or the pressure at implantation
of the valve? Do you have any insight into that?rdiovascular Surgery c Volume 145, Number 1 115
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DDrLaufer.All patients who came out of the operating room and
had finally been implanted with a pacemaker after the operation
had a pre-existing conduction disturbance, and if you study the
published data, they report a rate of 5% to 11% of permanent pace-
maker insertion after isolated aortic valve replacement. However,
in these cases, we also had isolated aortic and as aortic valve re-
placement plus CABG. So, I would say the profile of the patient
was, as evident by the European System for Cardiac Operative
Risk Evaluation, quite high.
Dr Harald C. Eichstaedt (Oldenburg, Germany). I am the co-
author of the following report, which discusses a different type of
sutureless valve. My question is related to the incidence of throm-
boembolic events that you have shown. Four patients had a stroke
in the early postoperative period and two later on. I would like to
ask you to explain your postoperative anticoagulation regimen.
Dr Laufer. The postoperative anticoagulation regimen was
low-molecular-weight heparin until the patients were switched
to warfarin (Coumadin), if there were no contraindications.
Dr Christopher Young (London, United Kingdom). I would
like to ask you briefly what you think the learning curve is for
the insertion of this.
Dr Laufer. This is a very good question. The learning curve in
this situation for 17 surgeons was there, because it was a com-
pletely new product. It is important to note that we photographed
the implantation procedure in the first cases. We evaluated the116 The Journal of Thoracic and Cardiovascular Surginflated stent below the valve with either a dental mirror or, in
some cases, with an endoscope to learn more about how the valve
sits in the outflow tract. The isolated aortic cases can be done with
a crossclamp time of 20 to 30 minutes.
Dr Young. Studying all those subgroups of ministernotomy, full
sternotomy, AVRplus, andAVR on its own, do you have a sense for
which group this had the largest impact in, who goes to intensive
care unit quicker, who goes home earliest?Where is the big effect?
Dr Laufer. It is too early to determine which group is the one
that profits most from this new valve, but basically all patients
will benefit, because the procedure time is substantially shorter,
the crossclamp time is substantially shorter. We do not have pled-
gets. I could not show, because the time was too short, the outflow
aspect from the ventricular side. We have no pledgets below the
valve. Thus, the hemodynamics are really superior. Also, com-
pared with a standard Magna valve, it is very easy to close the aor-
totomy, because the valve is hooked up below the annulus and not
with stitches at the annulus.
DrCharles R. Bridges (Charlotte, NC).Your mean crossclamp
time was 41 minutes. I was wondering whether during the course
of the study you noticed a decline in the crossclamp time so we
could have a better idea of the crossclamp time one could expect
after the learning curve.
Dr Laufer. A very good question, but we did not study these
statistics.ery c January 2013
